Background: Fibrosis in atrial myocardium is a common phenomenon for patients with atrial fibrillation (AF). Remodeling of connexins was found accompanying with AF. The aim of the study is to investigate whether it is by causing the remodeling of connexin 43 (Cx43) that the fibrosis of atrial muscle plays an important role during the initiation and maintenance of AF. Methods: Samples of right atrial appendage were taken from 24 patients with rheumatic valvular disease during surgery. Fibrosis and remodeling of Cx43 was examined by microscopy and ultramicroscopy technique and analyzed by image analyzer. The collagen volume fraction of type I (CVF-I) and the volume fraction of Cx43 (Cx43VF) were studied between AF and sinus rhythm (SR) groups. Results: (1) Microscopic examination demonstrated that CVF-I significantly increased and Cx43VF decreased in patients with AF compared to those with SR. (2) The CVF-I was negatively correlated with the Cx43VF. Conclusion: The results suggest that fibrosis and remodeling of Cx43 are involved in the pathophysiologic mechanism of human AF. Fibrosis of atrial muscle may play an important role in the process of AF by means of interfering with remodeling of connexins.

Keywords:
Atrial fibrillation, Connexin, Fibrosis, gap junction
1.
Li DQ, Feng YB, Zhang HQ: The relationship between gap junctional remodeling and human atrial fibrillation. Chin Med J, 2004;117:1256–1258.
2.
Kanagaratnam P, Cherian A, Stanbridge RD, et al: Relationship between connexins and atrial activation during human atrial fibrillation. J Cardiovasc Electrophysiol 2004;15:206–216.
3.
Boldt A, Wetzel U, Lauschke J, et al: Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004;90:400–405.
4.
Becker AE: How structurally normal are human atria in patients with atrial fibrillation? Heart Rhythm 2004;1:627–631.
5.
Grammer JB, Bohm J, Dufour A, et al: Atrial fibrosis in heart surgery patients: Decreased collagen III/I ratio in postoperative atrial fibrillation. Basic Res Cardiol 2005;100:288–294.
6.
Gros DB, Jongsma HJ: Connexins in mammalian heart function. Bioessays 1996;18:719–730.
7.
Jalife J, Morley GE, Vaidya D: Connexins and impulse propagation in the mouse heart. J Cardiovasc Electrophysiol 1999;10:1649–1663.
8.
Hagendorff A, Schumacher B, Kirchhoff S, et al: Conduction disturbances and increased atrial vulnerability in Connexin40-deficient mice analyzed by transesophageal stimulation. Circulation 1999;99:1508–1515.
9.
Wetzel U, Boldt A, Lauschke J, et al: Expression of connexins 40 and 43 in human left atrium in atrial fibrillation of different aetiologies. Heart 2005;91:166–170.
10.
Ausma J, van der Velden HM, Lenders MH, et al: Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat. Circulation 2003;107:2051–2058.
11.
Polontchouk L, Haefliger JA, Ebelt B, et al: Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol 2001;38:883–891.
12.
Koura T, Hara M, Takeuchi S, et al: Anisotropic conduction properties in canine atria analyzed by high-resolution optical mapping: preferential direction of conduction block changes from longitudinal to transverse with increasing age. Circulation 2002;105:2092–2098.
13.
Kostin S, Klein G, Szalay Z, et al: Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002;54:361–379.
14.
Weber KT: Cardiac interstitium in health and disease: the fibrillar collagen network. J Am CollCardiol 1989;13:1637–1652.
15.
Prystowsky EN, Benson DW Jr, Fuster V, et al: Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996;93:1262–1277.
16.
Verheule S, van Batenburg CA, Coenjaerts FE, et al: Cardiac conduction abnormalities in mice lacking the gap junction protein connexin 40. J Cardiovasc Electrophysiol 1999;10:1380–1389.
© 2007 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.